MICS safer and more effective than torsional phaco

Article

The new Custom Control Software on the MICS Millennium platform (Bausch & Lomb) results in less endothelial cell loss than torsional phacoemulsification performed on the Infiniti System (Alcon), according to a Greek study.

The new Custom Control Software on the MICS Millennium platform (Bausch & Lomb) results in less endothelial cell loss than torsional phacoemulsification performed on the Infiniti System (Alcon), according to a Greek study.

Panagiotis Zafirakis and colleagues from the Diagnostic and Therapeutic Eye Center, Hellenic Ophthalmochirourgiki, Athens conducted a randomized, comparative study of 120 eyes, which were assigned to phacoemulsification by MICS (60 eyes) or torsional ultrasound (60 eyes) modes. Bimanual phacoemulsification was performed using a quick chop technique.

Mean operating time (5.11 versus 7.30 minutes), effective phaco time (3±5.31 versus 9.37±6.80 seconds) and mean percentage of ultrasound power (6.67±1.66 versus 18.88±2.77) were statistically significantly shorter (p<0.01) with the MICS platform compared with the torsional system. Mean volume of irrigation fluid used (134±11.3 ml versus 175±27.5 ml) and mean endothelial cell loss (3.6% versus 5.3%) were also significantly lower with the MICS system (p<0.001). There were three capsular ruptures in the torsional group and none in the MICS group. Furthermore, there were seven cases of postoperative corneal fold or oedema in the torsional group and only one in the MICS group. Postoperative best-corrected visual acuity (BCVA) was similar in both groups.Overall, it was concluded, the MICS platform is a safer and more effective system than torsional phacoemulsification.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.